Quick answer on GLP-1 and menopause: GLP-1 weight-loss drugs work about as well after menopause as before it. In a post hoc analysis of the SURMOUNT-1 trial, women lost an average of 23% of their body weight on tirzepatide whether they were perimenopausal or postmenopausal, versus 3% on placebo.[2] They can be taken alongside hormone therapy, and one small study found women on hormone therapy lost more weight on semaglutide (16% vs 12% at a year), but that finding is not yet confirmed.[3][4]
This guide covers why weight and body shape change at menopause, what the trials found by menopause stage, how GLP-1 drugs fit with hormone therapy (HRT), and what to watch for with oral hormones, contraception, muscle and bone. For how these drugs work in general, see how GLP-1 drugs work and the GLP-1 basics hub.
Why weight and body shape change at menopause
The large US SWAN study followed women through the menopause transition with body scans. It found:[1]
- Fat gain doubled in speed at the start of the transition and continued until about 2 years after the final period.
- Lean mass (mostly muscle) started to fall at the same time.
- Weight itself did not speed up. It climbed steadily before menopause and leveled off afterward.
So the scale may not change much, but body composition does: more fat, less muscle, often more around the middle. That is the backdrop for using GLP-1 drugs in midlife.
GLP-1 results by menopause stage
| Trial or study | Women | Drug | Weight change |
|---|---|---|---|
| SURMOUNT-1, premenopause | Post hoc analysis | Tirzepatide 15 mg or highest tolerated dose | −26% vs −2% on placebo[2] |
| SURMOUNT-1, perimenopause | Post hoc analysis | Same | −23% vs −3%[2] |
| SURMOUNT-1, postmenopause | Post hoc analysis | Same | −23% vs −3%[2] |
| Mayo Clinic, on hormone therapy | 16 postmenopausal women | Semaglutide | −16% at 12 months[3] |
| Mayo Clinic, no hormone therapy | 90 postmenopausal women | Semaglutide | −12% at 12 months[3] |
In the SURMOUNT analysis, waist size fell by about 20 to 22 cm on tirzepatide across all three stages, and 97% to 98% of women lost at least 5% of their weight.[2] The authors reported similar results in SURMOUNT-3 and SURMOUNT-4. This was a post hoc analysis, meaning women were sorted by menopause stage after the trials ended, and several authors work for the drug’s maker.[2]
For semaglutide, the main obesity trial (STEP 1) reported an average 14.9% weight loss over 68 weeks in adults overall, versus 2.4% on placebo.[13] The Spanish Menopause Society’s 2026 position statement says semaglutide has the most menopause-specific evidence among these drugs, but that this evidence is still limited and mostly observational.[4] For full trial numbers, see semaglutide weight loss results and tirzepatide weight loss results.
GLP-1 drugs and hormone therapy (HRT)
Can you combine them? Menopause hormone therapy is not listed as a contraindication on the Wegovy or Zepbound labels; their contraindications are a personal or family history of certain thyroid cancers (MTC or MEN 2) and serious allergy to the drug.[10][6] The main practical issue is how oral hormones are absorbed, covered below.
Does HRT boost weight loss? In the Mayo Clinic study of 106 postmenopausal women on semaglutide, those using hormone therapy lost more weight at every check: 7% vs 5% at 3 months and 16% vs 12% at 12 months. More of them reached 5% and 10% weight loss, and the difference held after adjusting for other factors.[3] But only 16 women were on hormone therapy, and the study looked back at records rather than assigning treatment. The authors called for larger studies.[3]
The Spanish Menopause Society says this link is “hypothesis-generating” and should not justify starting hormone therapy just to increase weight loss.[4]
What HRT is for. Hormone therapy remains the most effective treatment for hot flashes, night sweats and vaginal symptoms, and it prevents bone loss. For women under 60 or within 10 years of menopause without contraindications, the Menopause Society says the benefits generally outweigh the risks.[5] The decision to use it should rest on those reasons, not on a GLP-1 prescription.
Oral hormones, contraception and stomach emptying
GLP-1 drugs slow how fast the stomach empties, which can change how quickly pills are absorbed.
- Zepbound (tirzepatide): the label warns it may reduce the effect of oral hormonal contraceptives. Women using them should switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase.[6]
- Menopause hormone therapy: no study has tested whether tirzepatide changes the effect of the oral progestogens used to protect the womb lining during hormone therapy. A 2026 review called the interaction biologically plausible but unproven, with any risk concentrated during the start and dose increases.[7]
- Semaglutide: in a study of healthy postmenopausal women, oral semaglutide did not change blood levels of the contraceptive hormones ethinylestradiol and levonorgestrel.[9] The Wegovy label notes the drug may affect absorption of other oral medicines.[10]
- A case report: a 51-year-old woman on oral estrogen had worse hot flashes and mood changes while her semaglutide dose was being raised. Symptoms settled after the increase was slowed.[8] One case cannot show cause, but it is a reason to mention symptom changes to your clinician.
Perimenopause and pregnancy. Pregnancy is still possible until menopause is confirmed. The Wegovy label advises stopping semaglutide at least 2 months before a planned pregnancy.[10] See GLP-1 drugs and unplanned pregnancy for more.
Do GLP-1 drugs help hot flashes?
No GLP-1 drug is approved for hot flashes. A 2026 scoping review found a few studies reporting improved hot flashes, but called for larger, more robust research.[12] For approved non-hormonal options, see our guide to peptides for menopause.
Muscle and bone after menopause
Women already lose lean mass during the menopause transition.[1] Weight loss on GLP-1 drugs also includes some lean mass, though a 2026 review notes that a drop in lean mass does not necessarily mean a meaningful loss of muscle strength or function.[11]
The Spanish Menopause Society recommends that GLP-1 treatment in menopause include attention to muscle health and fracture risk, resistance exercise, adequate protein and regular checks of physical function.[4] Our guide to GLP-1 muscle loss covers practical steps, and best peptides for bone health covers approved bone drugs.
Side effects
No menopause-specific side effect profile has been described. In the STEP 1 trial in adults overall, nausea and diarrhea were the most common side effects; they were usually mild to moderate and eased over time, and 4.5% stopped treatment because of stomach side effects.[13] See GLP-1 side effects for the full list and how to manage them.
Questions to ask your clinician
- Am I in perimenopause or postmenopause, and does that change which medicine fits?
- If I take oral estrogen or progesterone, should anything change while my GLP-1 dose is being increased?
- Do I need a different form of contraception while starting a GLP-1 drug?
- How will we protect my muscle and bone, and should I have a bone density scan?
- Is hormone therapy right for my symptoms, separate from weight?
For a broader look at midlife options, see best peptides for women over 40.
